Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Binimetinib

An oral inhibitor of the MEK1 and MEK2 kinases, approved in 2018 together with the BRAF inhibitor encorafenib for advanced melanoma with a BRAF V600 mutation, and later also for some lung cancers carrying the same mutation. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The ending '-metinib' marks MEK inhibitors: like trametinib and cobimetinib it is paired with a BRAF inhibitor, to block two successive steps of the same signalling pathway that drives tumour growth.

BinimetinibGo to the active ingredient →
BinimetinibActive ingredientBinimetinibCat. No. P-B083-001CAS 606143-89-9

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.